Clinical trial • Phase I • Oncology

PF-08046876 for Advanced solid tumors

Phase I trial of PF-08046876 for Advanced solid tumors. None/Not specified-controlled. 240 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Advanced solid tumors
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
03-09-2025
First CTIS Authorization Date
23-12-2025

Trial design

None/Not specified-controlled Phase I trial across 3 sites in Spain.

Comparator
None/Not specified
Target Sample Size
240
Trial Duration For Participant
1342

Eligibility

Recruits 240 Vulnerable population not selected; no special consent/assent handling described..

Vulnerable Population
Vulnerable population not selected; no special consent/assent handling described.

Recruitment

Planned Sample Size
240
Recruitment Window Months
44

Geography

Total Number Of Sites
3
Total Number Of Participants
240

Spain

Earliest CTIS Part Ii Submission Date
25-11-2025
Latest Decision Or Authorization Date
23-12-2025
Processing Time Days
28
Number Of Sites
3
Number Of Participants
70

Sites

Site Name
Hospital Universitario 12 De Octubre
Department Name
Medical Oncology
Principal Investigator Name
Guillermo de Velasco Oria de Rueda
Principal Investigator Email
gdevelasco.gdv@gmail.com
Contact Person Name
Guillermo de Velasco Oria de Rueda
Contact Person Email
gdevelasco.gdv@gmail.com
Site Name
Hospital Universitari Vall D Hebron
Department Name
Departamento de Oncologia- VHIO
Principal Investigator Name
Elena Garralda Cabanas
Principal Investigator Email
egarralda@vhio.net
Contact Person Name
Elena Garralda Cabanas
Contact Person Email
egarralda@vhio.net
Site Name
Hospital Universitario Fundacion Jimenez Diaz
Department Name
Medical Oncology
Principal Investigator Name
Bernard Gaston Doger de Speville Uribe
Principal Investigator Email
Bernard.doger@startmadrid.com
Contact Person Name
Bernard Gaston Doger de Speville Uribe
Contact Person Email
Bernard.doger@startmadrid.com

Sponsor

Primary sponsor

Full Name
Pfizer Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
PF-08046876

Related trials

Other published trials that may interest you.